Yunguang Sun1, Nicholas J Giacalone, Bo Lu. 1. Department of Radiation Oncology, Vanderbilt University School of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232-5671, USA.
Abstract
INTRODUCTION: Survivin, an inhibitor of apoptosis protein and key regulator of mitosis, is up-regulated in a variety of cancers and is often associated with a worse prognosis. Terameprocol down-regulates the Sp1-mediated transcription of survivin and Cdk1, which is important for cell cycle progression and many other proteins. Survivin inhibition has previously been shown to result in the induction of apoptosis and radiosensitization. METHODS: This study examined the effects of terameprocol administration on survivin transcription and expression in HCC2429 and H460 lung cancer cells. We also examined the combined effects of radiation and terameprocol on apoptosis and radiosensitivity. RESULTS: Using immunoblot analysis and luciferase assays, we confirmed that terameprocol decreases survivin transcription and protein expression. Ultimately, however, decreases in survivin expression failed to correlate with an increase in apoptosis. Nonetheless, clonogenic assay revealed that terameprocol induces increased radiosensitization in HCC2429 (dose enhancement ratio = 1.26, p = 0.019) and H460 (dose enhancement ratio = 1.18, p = 0.001) cells. Additionally, the data show no effect of terameprocol on cell cycle in either HCC2429 or H460 cells. CONCLUSIONS: Terameprocol significantly enhances the sensitivity of non-small cell lung carcinoma cell lines to radiation therapy, although the mechanism of action remains unclear. Further study is warranted to assess the potential of terameprocol as an agent that may enhance the therapeutic ratio of radiotherapy in lung cancer.
INTRODUCTION:Survivin, an inhibitor of apoptosis protein and key regulator of mitosis, is up-regulated in a variety of cancers and is often associated with a worse prognosis. Terameprocol down-regulates the Sp1-mediated transcription of survivin and Cdk1, which is important for cell cycle progression and many other proteins. Survivin inhibition has previously been shown to result in the induction of apoptosis and radiosensitization. METHODS: This study examined the effects of terameprocol administration on survivin transcription and expression in HCC2429 and H460 lung cancer cells. We also examined the combined effects of radiation and terameprocol on apoptosis and radiosensitivity. RESULTS: Using immunoblot analysis and luciferase assays, we confirmed that terameprocol decreases survivin transcription and protein expression. Ultimately, however, decreases in survivin expression failed to correlate with an increase in apoptosis. Nonetheless, clonogenic assay revealed that terameprocol induces increased radiosensitization in HCC2429 (dose enhancement ratio = 1.26, p = 0.019) and H460 (dose enhancement ratio = 1.18, p = 0.001) cells. Additionally, the data show no effect of terameprocol on cell cycle in either HCC2429 or H460 cells. CONCLUSIONS:Terameprocol significantly enhances the sensitivity of non-small cell lung carcinoma cell lines to radiation therapy, although the mechanism of action remains unclear. Further study is warranted to assess the potential of terameprocol as an agent that may enhance the therapeutic ratio of radiotherapy in lung cancer.
Authors: Kwang Woon Kim; Robert W Mutter; Christopher D Willey; Ty K Subhawong; Eric T Shinohara; Jeffrey M Albert; Geng Ling; Carolyn Cao; Young Jin Gi; Bo Lu Journal: Int J Radiat Oncol Biol Phys Date: 2007-04-01 Impact factor: 7.038
Authors: Juan F García; Francisca I Camacho; Manuel Morente; Máximo Fraga; Carlos Montalbán; Tomás Alvaro; Carmen Bellas; Angel Castaño; Ana Díez; Teresa Flores; Carmen Martin; Miguel A Martinez; Francisco Mazorra; Javier Menárguez; Maria J Mestre; Manuela Mollejo; Ana I Sáez; Lydia Sánchez; Miguel A Piris Journal: Blood Date: 2002-09-12 Impact factor: 22.113
Authors: Angel Mauricio Castro-Gamero; Kleiton Silva Borges; Daniel Antunes Moreno; Veridiana Kill Suazo; Mayara Missono Fujinami; Rosane de Paula Gomes Queiroz; Harley Francisco de Oliveira; Carlos Gilberto Carlotti; Carlos Alberto Scrideli; Luiz Gonzaga Tone Journal: Invest New Drugs Date: 2013-01-09 Impact factor: 3.850
Authors: Stuart A Grossman; Xiaobu Ye; David Peereboom; Myrna R Rosenfeld; Tom Mikkelsen; Jeffrey G Supko; Serena Desideri Journal: Neuro Oncol Date: 2012-02-08 Impact factor: 12.300
Authors: Nicole M Anders; Carlos G Romo; Avelina Hemingway; Manmeet S Ahluwalia; Michelle A Rudek Journal: J Pharm Biomed Anal Date: 2021-12-07 Impact factor: 3.935
Authors: Bradley T Scroggins; Jeffrey Burkeen; Ayla O White; Eun Joo Chung; Darmood Wei; Su I Chung; Luca F Valle; Shilpa S Patil; Grace McKay-Corkum; Kathryn E Hudak; W Marston Linehan; Deborah E Citrin Journal: Int J Radiat Oncol Biol Phys Date: 2017-10-12 Impact factor: 7.038